Oncolytics Biotech (TSE:ONC) Sets New 52-Week Low – Here’s Why

Shares of Oncolytics Biotech Inc. (TSE:ONC) reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as C$1.03 and last traded at C$1.05, with a volume of 63494 shares trading hands. The stock had previously closed at C$1.05.

Analyst Upgrades and Downgrades

Separately, Raymond James raised Oncolytics Biotech to a “moderate buy” rating in a research report on Thursday, November 14th.

Oncolytics Biotech Stock Up 2.9 %

The stock has a market cap of C$83.01 million, a price-to-earnings ratio of -2.84 and a beta of 1.35. The firm’s 50 day moving average is C$1.26 and its two-hundred day moving average is C$1.38. The company has a current ratio of 4.99, a quick ratio of 8.86 and a debt-to-equity ratio of 6.09.

Oncolytics Biotech (TSE:ONC) last announced its quarterly earnings data on Tuesday, November 12th. The company reported C($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of C($0.11) by C($0.01). During the same quarter last year, the firm earned ($0.14) EPS. On average, sell-side analysts predict that Oncolytics Biotech Inc. will post -0.41 EPS for the current year.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.